Post-money valuation equals pre-money valuation plus the amount of new capital raised. Investor ownership equals investment ÷ post-money. For example, a 5 million dollar investment at a 20 million dollar post-money gives the investor 25 percent. Post-money is also used to define ownership in post-money SAFEs. Because it includes new cash, post-money is not the same as the value of the business before the deal.

Why it matters

Post-money is the headline number in press releases. Founders should focus on the dilution math, not the headline.

Common pitfalls

•A high post-money valuation does not guarantee regulatory approval or product market success.
•Confusing a high valuation with adequate funding for long-term regulatory compliance can lead to underestimation of compliance costs.
•Failing to allocate sufficient capital from funding rounds, regardless of valuation, for critical quality and regulatory personnel can hinder compliance.
•Assuming investors fully understand the financial requirements for MedTech regulatory clearances and post-market obligations.

Sources

PitchBook - MedTech Coverage · PitchBook
NVCA Model Documents · NVCA
Silicon Valley Bank - Healthcare Reports · SVB
SEC capital-raising glossary: valuation · U.S. Securities and Exchange Commission

Open full page

Select term B to compare.

Why compare MedTech terms side by side?

MedTech terminology is full of pairs that look interchangeable but carry very different regulatory, clinical, and commercial consequences. Picking the wrong framework, pathway, or standard early in a project can add months to a submission, invalidate clinical evidence, or trigger an audit finding. Side-by-side comparison is the fastest way to surface those differences before they become costly mistakes.

Each comparison on this page pulls from the same vendor-neutral, sourced definitions used throughout the MedTech Terms glossary. You see the one-line summary, the formal definition, why it matters in practice, common pitfalls, and the primary sources (FDA guidance, EU MDR/IVDR articles, ISO/IEC standards, MDCG documents, IMDRF principles) that back each entry. That makes the comparison defensible in regulatory strategy memos, design reviews, and submission narratives.

Common comparison patterns

Regulatory pathway choice - 510(k) vs PMA, 510(k) vs De Novo, Abbreviated vs Special 510(k).
Quality systems - QSR vs ISO 13485, QMSR vs QSR.
Software classification - SaMD vs SiMD, Locked vs adaptive AI.
EU frameworks - MDR vs IVDR, CE Mark vs UKCA.
Cybersecurity artifacts - SPDX vs CycloneDX SBOM, CVE vs CVSS.
Post-market actions - Recall vs field action, Removal vs correction.

How to use this tool

Pick term A and term B from the dropdowns, or click a preset above. The URL updates with both slugs so you can bookmark or share the exact comparison with a colleague, a notified body reviewer, or your regulatory consultant. Click Open full page on either side for the complete entry, including FAQs, related terms, and the full citation list. If you are not sure which term to start with, browse the Categories view or the A-Z index.

MedTech Terms is a vendor-neutral community resource sponsored by Blue Goat Cyber. Definitions are written for educational use and are not legal or regulatory advice.